[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placenta-previa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placenta-previa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,72,99,125,161,182,209,229,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643938","effect-of-a-cervical-pessary-on-the-rate-of-bleeding-in-placenta-praevia-100643938",false,"NCT07667777","Effect of a Cervical Pessary on the Rate of Bleeding in Placenta Praevia","Prospective, Randomised, Multicentre Study to Investigate the Effect of a Cervical Pessary on the Rate of Bleeding in Patients With Placenta Praevia","Inclusion Criteria:\n\n* Age 18 to 45 years\n* Singleton pregnancy\n* Ultrasound-confirmed placenta previa (total or marginal) diagnosed between 20 and 30 weeks of gestation\n* Or low-lying placenta with placental edge less than 20 mm from the internal os\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Fetal malformations or chromosomal abnormalities detected by ultrasound\n* Uterine malformations\n* Silicone allergy\n* Cervical dilation\n* Cervical or vaginal infection\n* Cervical cancer\n* Cervical tears, cervical scarring, or ectopic cervical tissue\n* Preterm prelabor rupture of membranes\n* Regular uterine contractions\n* Cerclage in place\n* Pessary already in place\n* Active bleeding\n* Genital prolapse grade III or IV","FEMALE","18 Years","45 Years",{"count":20,"type":21},190,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether use of a cervical pessary can reduce vaginal bleeding and prolong pregnancy in women with placenta previa or a low-lying placenta. Placenta previa is a condition in which the placenta covers or lies close to the cervix and may cause serious bleeding, preterm birth, and complications for both the pregnant woman and the baby.\n\nIn this prospective, randomized, multicenter study, eligible women with singleton pregnancies and ultrasound-confirmed placenta previa or low-lying placenta between 20 and 30 weeks of gestation will be assigned either to treatment with an Arabin cervical pessary or to standard care without a pessary. The study will compare bleeding-related outcomes and pregnancy duration between the two groups.\n\nThe study is designed to determine whether a cervical pessary is a safe and effective intervention for reducing bleeding-related complications and prolonging gestation in this high-risk pregnancy population.",[27],"Placenta Previa","NOT_YET_RECRUITING","2026-06-19",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Asklepios proresearch","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100627711","evaluation-of-cervical-invasion-and-length-in-placenta-accreta-patients-100627711","NCT07452185","Evaluation of Cervical Invasion and Length in Placenta Accreta Patients","Evaluation of Placental Cervical Invasion and Cervical Length in Patients With Placenta Accreta","Inclusion Criteria:\n\n* Pregnant women aged 18-45 years with suspected or confirmed PAS based on prenatal ultrasound (e.g., placenta previa with at least one prior cesarean section).\n* Gestational age between 18-32 weeks at enrollment to allow for serial monitoring.\n* Singleton pregnancy.\n* High-risk features such as history of multiple cesarean sections, antepartum bleeding, or abnormal placental location on initial screening.\n\nExclusion Criteria:\n\n* Multiple gestation.\n* Pre-existing cervical incompetence or cerclage placement prior to enrollment. -Transfer from outside facilities without complete prenatal records.",{"count":49,"type":21},200,"16 Weeks","OBSERVATIONAL","Placenta accreta spectrum (PAS), also called morbidly adherent placenta, is a serious pregnancy problem where the placenta attaches too deeply to the uterus wall and does not come out normally after birth. This often happens after previous cesarean sections or when the placenta is low (placenta previa). It can cause heavy bleeding, serious complications, and danger to the mother.\n\nThis study will look at pregnant women with PAS at Sohag University Hospital in Egypt. Researchers will use ultrasound to check two things:\n\nHow much the placenta has invaded the cervix (the lower part of the uterus). The length of the cervix.\n\nThe main goals are to find out:\n\nHow common cervical invasion is in PAS cases. What happens to women who have this invasion (outcomes like bleeding or surgery needs).\n\nIf a short cervix is linked to early labor (preterm birth). Women with confirmed PAS will join this observational study from March 2026 to January 2028. They will have extra ultrasound scans during pregnancy. No new treatments or drugs are tested - the study only collects information from routine care and scans to better understand the condition.\n\nThis research may help doctors predict risks earlier, plan safer deliveries, and improve care for mothers and babies with PAS in the future.",[54,55,27],"Placenta Accreta Spectrum","Placenta Accreta",[57,58,59,60,61,62],"Placenta accreta spectrum","Cervical invasion","Cervical length","Placenta accreta","Ultrasound evaluation","Preterm labor","2026-03-01",{"date":65,"type":32},"2026-03-05",{"date":63,"type":21},{"date":68,"type":21},"2028-01-01",{"name":70,"class":71},"Sohag University","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":40},"100625478","phase-3-tranexamic-acid-vs-vasopressin-in-placenta-previa-trial-100625478","NCT07423156","Tranexamic Acid vs Vasopressin in Placenta Previa Trial","Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Patients Undergoing Cesarean Section","TXA-VASO-PP","Inclusion Criteria:\n\nWomen of reproductive age\n\nAge 18-45 years\n\nDiagnosed placenta previa in current pregnancy\n\nScheduled for elective cesarean section\n\nSingleton pregnancy\n\nExclusion Criteria:\n\nEmergency cesarean section\n\nPlatelet or coagulation disorder\n\nUse of anti-platelet or anti-coagulant drugs\n\nPrevious history of postpartum hemorrhage\n\nChronic liver disease\n\nChronic kidney disease\n\nGestational diabetes\n\nPregnancy-related hypertensive disorders\n\n\\-",{"count":81,"type":21},58,[83],"PHASE3","Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality. Different pharmacological agents have been used to minimize intraoperative hemorrhage. Tranexamic acid is an antifibrinolytic agent, while vasopressin reduces blood loss by causing vasoconstriction and myometrial contraction at the injection site. Both drugs have been used separately in placenta previa cases, however direct comparison between tranexamic acid and vasopressin is limited.\n\nThis randomized controlled trial will be conducted at the Department of Obstetrics \\& Gynecology, AIMC\u002FJinnah Hospital Lahore. A total of 58 women (29 in each group), aged 18-45 years, with singleton pregnancy and diagnosed placenta previa undergoing elective cesarean section will be included. Participants will be randomly allocated into two groups. Group A will receive 1 gram tranexamic acid diluted in 20 ml of 5% dextrose intravenously 15 minutes before cesarean section. Group B will receive 4 units vasopressin diluted in 20 ml normal saline injected at placental implantation site after delivery of placenta.\n\nThe primary outcome will be intraoperative blood loss measured by gauze saturation assessment and suction drain measurement. The study will help determine which drug is more effective in reducing blood loss in placenta previa patients undergoing cesarean section.",[27],[87,88,89,90],"Obstetric Hemorrhage","Cesarean Section","Tranexamic Acid","Vasopressin","2026-02-13",{"date":93,"type":32},"2026-02-20",{"date":63,"type":21},{"date":96,"type":21},"2026-08-31",{"name":98,"class":71},"Allama Iqbal Medical College",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100594938","planned-delivery-at-37-versus-36-weeks-in-pregnancies-with-placenta-previaand-accreta-100594938","NCT07025954","Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta","Planned Delivery at 37 Versus 36 Weeks in Pregnancies Complicated byPlacenta Previa and Accreta: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 28-34 weeks of gestation.\n* Both ultrasound and MRI indicate placenta previa with placenta accreta spectrum (PAS).\n* Planned to undergo cesarean delivery at the participating study hospitals.\n* Agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Multiple gestation.\n* Other obstetric complications (e.g., preeclampsia, vasa previa), and severe maternal medical conditions (e.g., uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, liver cirrhosis).\n* Major uterine structural anomalies (e.g., uterine didelphys, Uterine tumors ≥5 cm).\n* Estimated fetal weight \\\u003C3rd percentile for gestational age, major congenital anomalies, intrauterine fetal demise.",{"count":107,"type":21},600,[24],"Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1\u002F3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative\u002Fpostoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0\u002F7-37 6\u002F7 weeks of gestation with those at 36 0\u002F7-36 6\u002F7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.",[27,54,111,112,113],"Antepartum Bleeding","Emergency Cesarean Section","Preterm Birth Complication","RECRUITING","2025-07-11",{"date":117,"type":32},"2025-07-16",{"date":119,"type":32},"2025-07-12",{"date":121,"type":21},"2027-03-01",{"name":123,"class":71},"The Third Affiliated Hospital of Guangzhou Medical University",6,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":51,"phases":4,"briefSummary":136,"conditions":137,"keywords":143,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":124},"100586658","association-of-assisted-reproductive-technologies-parameters-with-the-perinatal-outcome-100586658","NCT06918236","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome in Singleton and Multiple Pregnancies: A Multicenter Prospective Cohort Study","Inclusion Criteria\n\n* Singleton or multiple pregnancies\n* Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation\n\nExclusion Criteria\n\n* Known genetic anomalies diagnosed before or after birth\n* Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects",true,{"count":134,"type":21},12084,"9 Months","The goal of this prospective cohort study is to examine how different parameters of assisted reproductive technologies (ART) are associated with the perinatal outcome in individuals with singleton or multiple gestations. The main questions it aims to answer are:\n\nAre ART pregnancies associated with a higher risk of:\n\n* Small for gestational age neonates?\n* Fetal growth restriction, either early- or late-onset?\n* Development of preeclampsia?\n* Stillbirth (intrauterine fetal death after 22 weeks not due to known anomalies)?\n* Are certain ART parameters-such as the type of fertilization (e.g., IVF vs. ICSI), embryo stage at transfer, use of fresh vs. frozen embryos, or ovarian stimulation protocols-more strongly associated with adverse outcomes?\n\nAre ART pregnancies associated with placental and umbilical cord abnormalities, including:\n\n* Placenta previa?\n* Vasa previa?\n* Single umbilical artery?\n* Velamentous or marginal cord insertion?\n\nResearchers will compare outcomes between pregnancies conceived through ART and those conceived spontaneously.\n\nParticipants will:\n\n* Be individuals aged 18 or older undergoing routine first-trimester ultrasound between 11 and 14 weeks of gestation\n* Provide detailed medical, obstetric, and ART-related information\n* Undergo routine prenatal assessments, including ultrasound evaluations of fetal growth, Doppler studies, and placental characteristics\n* Have perinatal outcomes such as gestational age at birth, mode of delivery, birthweight, and complications systematically recorded\n\nStatistical models will be used to adjust for confounding factors such as maternal age, BMI, parity, and smoking.\n\nThe aim is to better understand how ART and specific ART parameters may influence maternal and neonatal health and to improve counseling and clinical care for people using fertility treatments.",[138,139,140,27,141,142],"Fetal Growth Restriction (FGR)","Preeclampsia","Stillbirth","Vasa Previa","Small for Gestational Age (SGA)",[144,139,145,146,147,148,149,142,150,151],"fetal growth restriction","stillbirth","placenta previa","vasa previa","Assisted reproductive techniques","ART","IVF","ICSI","2025-04-05",{"date":154,"type":32},"2025-04-09",{"date":156,"type":32},"2024-10-01",{"date":158,"type":21},"2028-12",{"name":160,"class":71},"Aristotle University Of Thessaloniki",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":132,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":40},"100582789","syncytiotrophoblast-derived-extracellular-vesicles-in-placenta-previa-and-accreta-spectrum-100582789","NCT06867874","Syncytiotrophoblast-derived Extracellular Vesicles in Placenta Previa and Accreta Spectrum","Shedding of Syncytiotrophoblast-derived Extracellular Vesicles is Increased in Placenta Previa and Accreta Spectrum: a Case-control Study.","PAS","Inclusion Criteria:\n\n* Pregnant women with diagnosis of placenta previa and accreta spectrum (cases)\n* Healthy pregnant women\n* \\> 18 years\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Twin pregnancies\n* Chronic Infections\n* Cancers\n* Unable to give the written consent",{"count":170,"type":21},70,[24],"The main goal of this case-control study is to quantify the levels of circulating syncytiotrophoblast-derived extracellular vesicles (STBEVs) in maternal blood in a population of women with placenta previa and placenta accreta spectrum.",[27,54],"2025-03-05",{"date":176,"type":32},"2025-03-10",{"date":178,"type":32},"2023-07-10",{"date":63,"type":21},{"name":181,"class":71},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":4,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100563738","causal-relationship-between-plasma-vegf-family-proteins-and-placenta-previa-a-two-sample-mendelian-randomization-study-100563738","NCT06620068","Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study","Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study","VEGF PP","Inclusion Criteria:\n\n* Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.\n\nExclusion Criteria:\n\n* Participants with incomplete or missing data on plasma VEGF levels or placenta previa.","ALL",{"count":192,"type":21},207473,"This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.",[27],[196,197,198,199,200],"Vascular Endothelial Growth Factor (VEGF)","Mendelian Randomization","Angiogenesis","Pregnancy Complications","Placental Development","2024-09-26",{"date":156,"type":32},{"date":204,"type":21},"2024-09-25",{"date":206,"type":21},"2024-12-01",{"name":208,"class":71},"Guangzhou Institute of Respiratory Disease",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100561362","clinical-outcomes-of-placenta-previa---an-individualized-scoring-system-100561362","NCT06589180","Clinical Outcomes of Placenta Previa - an Individualized Scoring System","Inclusion Criteria:\n\nPregnant women diagnosed with placenta previa at time of routine second trimester ultrasound (18 to 21 weeks of gestation).\n\nAged 18 years old or above. Diagnosed with PP, followed-up antenatally and delivered within the same center.\n\nAuthorization to use anonymous patient data for research purposes\n\nExclusion Criteria:\n\nInadequate documentation. Non-compliance to antenatal care. Previous 1 or more Cesarean deliveries. Previous uterine surgeries that approach the uterine cavity (myomectomy). Known untreated uterine septum. Maternal chronic medical condition that is associated with higher risk of placental insufficiency (including chronic hypertension, pregestational diabetes, chronic renal disease, autoimmune disease).\n\nFetal major congenital anomalies","55 Years",{"count":217,"type":21},1000,"The objective of the study is to develop a machine learning -based prediction model for patients with placenta previa . The model will be based on patient characteristics, clinical assessment, and disease features to predict disease course, prognosis and establish an individualized plan of care. Individualized management plan comprises timing of delivery, mode of delivery, need for hospital admission, postpartum hemorrhage management plan, and perioperative care.\n\nThe primary outcome is to predict maternal complications, primarily major antepartum hemorrhage (APH), defined as blood loss of 50-1000 ml.",[27],"2024-09-05",{"date":222,"type":32},"2024-09-19",{"date":224,"type":21},"2025-01-04",{"date":226,"type":21},"2026-05-04",{"name":228,"class":71},"Assiut University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":40},"100500899","sonographic-parameters-and-risk-of-antepartum-hemorrhage-in-asymptomatic-women-with-placenta-previa-a-cohort-study-100500899","NCT05802251","Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study","Inclusion Criteria:\n\n* Asymptomatic women diagnosed with placenta previa according to RCOG (GTG No. 27a, 2018): placenta lies directly over the internal os for pregnancies more than 16 weeks' gestation on transabdominal or transvaginal scanning.\n* Gestational age between 28 till 37 weeks' gestation (as delivery should be considered between 36 and 37 weeks of gestation for women presenting with uncomplicated placenta previa)\n\nExclusion Criteria:\n\n* Multiple pregnancies.\n* Threatened preterm labor or preterm rupture of membranes.\n* History of bleeding in the current pregnancy.\n* Polyhydraminos (AFI \\> 25 cm).\n* History of cervical surgery (cone biopsy).\n* Presence of cervical cerclage.\n* Maternal use of vaginla progesterone.\n* History of maternal disease (hypertensive, DM, Cardiac).\n* Fetal malformation or growth restriction",{"count":236,"type":21},68,"The aim of this study is to evaluate the effectiveness of ultrasonographic parameters (cervical length, placental thickness and distance placental edge from internal os of the cervix) in predicting the risk of antepartum hemorrhage and emergency cesarean delivery in asymptomatic women with placenta previa.",[27],"2024-07-29",{"date":241,"type":32},"2024-07-30",{"date":243,"type":32},"2022-06-01",{"date":245,"type":21},"2024-08",{"name":247,"class":71},"Ain Shams University",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":132,"sex":16,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100555703","efficacy-of-topical-tranexamic-acid-in-reducing-blood-loss-during-cs-in-patients-with-placenta-previa-100555703","NCT06515535","Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During CS in Patients With Placenta Previa","Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During Elective Cesarean Delivery in Patients With Placenta Previa","Inclusion Criteria:\n\n* Age: 20-40 years old.\n* BMI less than 30 kg\u002Fm2.\n* Pregnancy of singleton living fetus.\n* Placenta previa by ultrasound assessment\n* Gestational age \\> 36 weeks.\n\nExclusion Criteria:\n\n* Women with a history of any medical disorder with pregnancy, e.g., Gestational diabetes and hypertension.\n* Women with systemic diseases, e.g., diabetes mellites, systemic immune disorders such as systemic lupus erythematosus\n* Women with bleeding tendency or coagulopathy.\n* Women on anticoagulants or hemodynamically unstable women.\n* Women with uterine abnormalities, such as fibroids or polyps.\n* Emergency termination of pregnancy.\n* Intrauterine fetal death.\n* Pregnancy with obstetric hemorrhage, e.g., antepartum hemorrhage\n* Cases of placenta accrete spectrum disorder or placental abruption\n* Women with known allergies to Tranexamic acid","20 Years","40 Years",{"count":258,"type":21},56,[24],"Objectives: To evaluate the efficacy of topical tranexamic acid applied on the placental bed after placental delivery to reduce blood loss during cesarean delivery in women with placenta previa.\n\nPatients will be randomly assigned into two groups:\n\nGroup (A) - Study group (n=28): The topical tranexamic acid group will receive topical tranexamic acid after placental delivery applied on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%, in addition to the IV infusion of 1g tranexamic acid (2 ampules 500ug) diluted with 20ml of 5% glucose administered just after delivery of the fetus.\n\nGroup (B) - Control group (n=28): The intravenous tranexamic acid group will receive only an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.",[27],"2024-07-17",{"date":264,"type":32},"2024-07-23",{"date":266,"type":21},"2024-07-24",{"date":268,"type":21},"2024-12-31",{"name":270,"class":71},"Cairo University"]